+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Artificial Blood and Plasma: Global Markets to 2027

  • PDF Icon


  • 120 Pages
  • August 2023
  • Region: Global
  • BCC Research
  • ID: 4495392
UP TO OFF until Aug 31st 2033

Quick Summary:

In a rapidly evolving healthcare landscape, understanding the dynamics of the global artificial blood market can offer valuable insights for strategic decision-making. Delving into research and development, clinical trial outcomes, and the commercial demand for artificial blood products, this comprehensive study profile the industry, forecast trends, and highlight the critical factors shaping the market. This includes close scrutiny of artificial oxygen carrier products - an increasingly significant segment in this space.

Moreover, the importance of market players' analyses cannot be overstated, especially for senior business executives planning strategic ventures. This report offers valuable profiles of key market players, detailing their business segments, financials, product portfolios, and recent developments. Also included are trends about emerging technologies and a thorough product analysis. With an outlook on industry investments and significant deals, this report is a crucial tool for anticipating market growth and creating robust competitive strategies.

The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes

  • 41 tables
  • An overview of the global markets for artificial blood
  • Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the market potential and characterization of artificial blood market by product, application, and region
  • Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
  • Coverage of recent advances, emerging technologies, and developments of the industry
  • Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
  • Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma
Frequently Asked Questions about the Global Artificial Blood Market

What is the estimated value of the Global Artificial Blood Market?

The Global Artificial Blood Market was estimated to be valued at $26.1 Million in 2023.

What is the growth rate of the Global Artificial Blood Market?

The growth rate of the Global Artificial Blood Market is 9.2%, with an estimated value of $40.5 Million by 2028.

What is the forecasted size of the Global Artificial Blood Market?

The Global Artificial Blood Market is estimated to be worth $40.5 Million by 2028.

Who are the key companies in the Global Artificial Blood Market?

Key companies in the Global Artificial Blood Market include Aurum Biosciences, Erypharm, Hemoglobin Oxygen Therapeutics LLC., Hemarina, Kalocyte Inc., Nano Sanguis S.A, Nuvox Pharma LLC., Prolong Pharmaceuticals, LLC, Red C Biotech and Virtech Bio.

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • What's New in this Update?
  • Methodology
  • Information Sources
  • Geographic Breakdown
Chapter 2 Summary and Highlights
  • Market Overview
Chapter 3 Market Overview
  • Introduction
  • Is There a Problem With Human Blood?
  • Emerging Needs for Artificial Blood
  • Artificial Blood Will Be Useful in Dealing With the Risks of Infection
  • Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
  • Artificial Blood is Needed to Deal With Unexpected Demands on the Blood System
  • Hurdles in the Development of Artificial Blood Products
  • Ideal Characteristics of Artificial Blood
  • Artificial Blood Over Human Blood
  • Applications
  • Surgeries
  • Emergency Resuscitation
  • For Short-Term Use
  • Where More Effective Than Human Blood
  • Rejections Due to Religious Beliefs
  • Challenges in Artificial Blood Development
Chapter 4 Market Dynamics
  • Drivers
  • Increasing Demand for Blood Transfusions
  • Risks and Challenges Associated With Blood Transfusions
  • Shortage of Blood Supply
  • Barriers
  • Low Rate of Product Approvals
  • Product Acceptance
  • Product Pricing
  • Opportunities
  • Impact of Covid-19
Chapter 5 Artificial Blood by Source
  • Introduction
  • Artificial Blood Developed from Human Blood
  • Artificial Blood Developed from Animal Blood
  • Artificial Blood Developed Using Recombinant Technology
  • Surface Modified Hemoglobin
  • Cross-Linked Hemoglobin
  • Polymerized Hemoglobin
  • Encapsulation
  • Genetically Engineered Recombinant Hemoglobin
  • Natural Hemoglobin
Chapter 6 Artificial Blood by Type
  • Introduction
  • Perfluorocarbon Emulsions
  • General Characteristics of Perfluorocarbons
  • Emulsion Selection
  • Historical Developments of Perfluorocarbon Emulsions
  • First Generation of Pfcs
  • Second Generation of Pfcs
  • Third Generation of Pfcs
  • Hemoglobin-Based Oxygen Carriers
  • General Characteristics of Hbocs
  • Historical Events: Hemoglobin Solutions
Chapter 7 Market Estimation
  • Introduction
  • Potential Market for Artificial Blood
  • Artificial Blood Market, by Source
  • Blood (Animal/Human)
  • Synthetic Polymers
  • Artificial Blood Market, by Type
  • Hemoglobin-Based Oxygen Carriers
  • Perfluorocarbon-Based Products
  • Artificial Blood Market, by Region
  • North America
  • Europe
  • Emerging Markets
Chapter 8 Emerging Technologies and Developments
  • Overview
  • Emerging Technologies
  • Nanocapsule Technology
  • Stem Cells
  • Other Ongoing Research for Blood Substitutes
Chapter 9 Product Analysis
  • Introduction
  • Product Safety
  • Product Effectiveness
  • Product Cost
  • Legal Implications
  • Product Analysis of Some of the Products Under Development
  • Hemopure
  • Hemo2Life
  • Hemotech
  • Nano2 (Ddfpe)
  • Sanguinate
  • Vidaphor
  • Clinical Trials
  • Product Description of Some of the Products in Preclinical and Early Phase I Stage
  • Erythromer
  • Hemoglobin Vesicles
  • Oxyvita
  • Oxybridge
Chapter 10 Patent Analysis
  • Introduction
  • Fda Regulation
  • Fda Good Manufacturing Practices and Reporting
  • Patent Analysis
Chapter 11 Competitive Intelligence
  • Strategic Developments
  • Competitive Analysis
Chapter 12 Company Profiles
  • Aurum Biosciences
  • Erypharm
  • Hemoglobin Oxygen Therapeutics LLC.
  • Hemarina
  • Kalocyte Inc.
  • Nano Sanguis S.A
  • Nuvox Pharma LLC.
  • Prolong Pharmaceuticals, LLC
  • Red C Biotech
  • Virtech Bio
List of Tables
Summary Table: Global Market for Artificial Blood, Through 2028
Table 1: Historical Events Related to Blood Transfusion, 1628-2022
Table 2: Potential Benefits and Application Areas of Artificial Blood
Table 3: Average Number of Blood Units Required During Particular Medical Conditions
Table 4: The Challenges Associated with the Development of Artificial Blood
Table 5: Common Challenges to the Blood Transfusion Continuum in LMICs.
Table 6: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 7: Pros and Cons of Artificial Blood Developed from Human Blood
Table 8: Pros and Cons of Artificial Blood Developed from Animal Blood
Table 9: Pros and Cons of Artificial Blood Developed from Recombinant Blood
Table 10: Summary of Acellular Hb-Based Oxygen Carriers
Table 11: Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
Table 12: Potential Clinical Applications of Oxygen Carriers
Table 13: Composition of PFC Emulsion-Based Artificial Blood Products
Table 14: First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 15: Comparative Study of Second-Generation PFCs
Table 16: PFC Emulsion Products and Current Status
Table 17: Comparative Study Between RBCs and HBOCs
Table 18: HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 19: Examples of HBOC Products Developed, by Various Companies
Table 20: Global Market for Artificial Blood, Through 2028
Table 21: Current Cell Sources and Strategies for Ex-vivo RBC Generation
Table 22: List of Discontinued Blood Substitutes
Table 23: Hemopure: Raw Material and Method Overview
Table 24: Hemopure: Product Characteristics
Table 25: Hemopure: Advantages and Disadvantages
Table 26: Summary of Clinical Trials of Hemopure (HBOC-201), 2023
Table 27: HemO2life: Raw Material and Method
Table 28: HemO2life: Advantages and Disadvantages
Table 29: HemO2life: Product
Table 30: Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
Table 31: Hemotech: Raw Material and Method Overview
Table 32: HemoTech: Advantages and Disadvantages
Table 33: NanO2 (DDFPe): Raw Material and Method Overview
Table 34: NanO2 (DDFPe): Advantages and Disadvantages
Table 35: NanO2 (DDFPe): Clinical Trials, 2023
Table 36: Sanguinate: Raw Material and Method Overview
Table 37: Sanguinate: Advantages and Disadvantages
Table 38: Sanguinate: Clinical Trials, 2023
Table 39: Vidaphor: Raw Material and Method Overview
Table 40: Vidaphor: Advantages and Disadvantages
Table 41: Vidaphor: Clinical Trials, 2023

List of Figures
Summary Figure: Global Market for Artificial Blood, 2020-2028
Figure 1: The Blood Continuum
Figure 2: Medical Use of Human Red Blood Cells in the U.S., 2019
Figure 3: Estimated Number of New Cancer Cases from 2020 to 2040
Figure 4: Discards of Blood Donations, by Reason, 2018
Figure 5: Artificial Blood Manufactured from Different Sources
Figure 6: History of HBOCs Developed Using Recombinant Technology
Figure 7: Classification of Modified Hemoglobin Solution Based on Methods
Figure 8: Classification of Different Types of Oxygen Carriers
Figure 9: Generations of Perfluorocarbon Emulsions
Figure 10: Advantages and Disadvantages of PFC Emulsions
Figure 11: Evolution of HBOCs
Figure 12: Advantages and Disadvantages of HBOCs
Figure 13: Global Potential Market for Artificial Blood, by Application, 2028
Figure 14: Biosynthetic RBC vs Artificial Blood Substitutes
Figure 15: Artificial Blood: Parameters for Product Analysis
Figure 16: Hemopure: Product Analysis
Figure 17: HemO2life: Product Analysis
Figure 18: NanO2 (DDFPe): Product Analysis
Figure 19: Sanguinate: Product Analysis
Figure 20: Current Competition in the Global Artificial Blood Market

Executive Summary

The human body contains a vital fluid called blood, which delivers oxygen and nutrients to the body’s cells and carries waste products away from the cells in a gas exchange process. The artificial blood being developed is intended to satisfy some of the functions of biological blood, particularly in humans.

Currently, two fundamental approaches to artificial blood are being taken: perfluorocarbons and hemoglobin-based oxygen carriers.

Safe and timely access to blood transfusion is crucial for saving lives and enhancing health. Unfortunately, numerous patients needing transfusions face difficulty obtaining secure blood supplies promptly. Blood transfusions are done for several conditions, such as severe injury or trauma with significant blood loss, surgery, childbirth, anemia, cancer, kidney failures and others. The blood shortage and the risks and challenges associated with donor blood have led to the development of artificial blood. Notably, the potential market for artificial blood is very high, and estimated to be around $22.6 billion in 2028 and hence the market needs products which would cater to such high unmet need.

The research for finding a potential alternative for blood, has been ongoing for centuries, but the results have been disappointing. This is mainly because of the adverse reactions associated with the developed products. Because of this, these products have been terminated or discontinued during clinical development. The poor success rate of the products led to losses for the companies, because of which they have filed for bankruptcy or are out of business.

Recently, it has been observed that companies are focusing on developing products that would address the shortcomings of the failed or existing products in the pipeline. Some of these include the development of freeze-dried HBOCs, Erythromer (from Kalocyte) (which is based on nanocapsule technology), and biosynthetic red blood cells (producing red blood cells from stem cells), being developed by companies such as Erypharma and Red C Biotech. Researchers are also focusing on the development of artificial whole blood by combining three synthetic components: freeze-dried platelet surrogates, freeze-dried red blood cell surrogates, and freeze-dried plasma.

The artificial blood market was estimated to be $23.9 million in 2022 and is forecasted to grow at a compound annual growth rate (CAGR) of 9.2% to reach a value of $40.5 million through 2028. The market value is low because there are no approved products for artificial blood. Hemopure is the only marketed product for anemia and is approved in South Africa and Russia and used under an expanded access program in the U.S. Currently, the company doesn’t have the infrastructure and funds to produce the product and the company reported no revenue in 2021. In 2022, HemO2life from Hemarina was approved for use as an additive for kidney grafts in the European Union. There are no approved products for routine clinical use in the U.S., which is the primary market. A similar product for graft preservation is being developed by VirTechBio-OxyBridge-which is in development and anticipated to enter the U.S. market by 2026. There are companies with products in Phase II and Phase II/III development, but the products might not be approved in the forecast period or enter the market by 2028. However, future approvals will help cater to the high unmet need in the market.

Factors leading to the growth of the market are increasing demand for blood transfusions and risks and challenges associated with blood transfusions and shortage of blood supply. Factors such as low rate of approvals, product acceptance, and higher pricing act as barriers to the market. The market is dominated by startup and private biotech companies. Key players in the market include Hemarina, NuvOx Pharmaceuticals, VirTech Bio, and Prolong Pharmaceuticals.

Companies Mentioned

  • Aurum Biosciences
  • Erypharm
  • Hemoglobin Oxygen Therapeutics LLC.
  • Hemarina
  • Kalocyte Inc.
  • Nano Sanguis S.A
  • Nuvox Pharma LLC.
  • Prolong Pharmaceuticals, LLC
  • Red C Biotech
  • Virtech Bio